Variables | Category | Overall (N = 1920) | Anemia status | P-value | Exp(B) | 95% Wald CI for Exp (B) | ||
---|---|---|---|---|---|---|---|---|
N (%) | Anemic N = 798 (41.6%) | Non-anemic N = 1122(58.4%) | Sign | AOR | Lower | Upper | ||
Age of ART initiation | < 35 years | 660 (34.4%) | 278 (42.1%) | 382 (57.9%) | 0.406 | 1.202 | 0.778 | 1.858 |
35–45 years | 798 (41.6%) | 332 (41.6%) | 466 (58.4%) | 0.549 | 1.136 | 0.749 | 1.723 | |
> 45 years | 462 (24.1%) | 188 (40.7%) | 274 (59.3%) |  – | 1 |  – |  – | |
Sex | Male | 732 (38.1%) | 337 (46.0%) | 395 (54.0%) | 0.011 | 1.527 | 1.102 | 2.114 |
Female | 1188 (61.9%) | 461 (38.8%) | 727 (61.2%) |  – | 1 |  – |  – | |
Residence | Urban | 1422 (74.1%) | 561 (39.5%) | 861 (60.5% |  – | 1 |  – |  – |
Rural | 498 (25.9%) | 237 (47.6%) | 261 (52.4%) | 0.056 | 1.388 | 0.992 | 1.943 | |
Educational status | No | 294 (15.3%) | 120 (40.8%) | 174 (59.2%) | 0.750 | 0.918 | 0.540 | 1.559 |
Primary | 528 (27.5%) | 230 (43.6%) | 298 (56.4%) | 0.710 | 0.914 | 0.568 | 1.470 | |
Secondary | 786 (40.9%) | 314 (39.9%) | 472 (60.1%) | 0.447 | 0.847 | 0.553 | 1.299 | |
Tertiary | 312 (16.2%) | 134 (42.9%) | 178 (57.1%) |  – | 1 |  – |  – | |
WHO clinical stage | Stage I | 246 (12.8%) | 85 (34.6%) | 161 (65.4%) | 0.210 | 0.724 | 0.437 | 1.200 |
Stage II | 336 (17.5%) | 146 (43.5%) | 190 (56.5%) | 0.998 | 1.000 | 0.674 | 1.486 | |
Stage III/IV | 1338 (69.7%) | 567 (42.4%) | 771 (57.6%) |  – | 1 |  – |  – | |
Baseline CD 4 count | < 200 cell/μl | 480 (25.0%) | 177 (36.9%) | 303 (63.1%) | 0.072 | 0.737 | 0.528 | 1.028 |
> 200 cell/μl | 1440 (75.0%) | 621(43.1%) | 819 (56.9%) |  – | 1 |  – |  – | |
BMI at baseline | Under weight | 582 (30.3%) | 266 (45.7%) | 316 (54.3%) | 0.430 | 1.219 | 0.746 | 1.991 |
Normal | 1026 (53.4%) | 405 (39.5%) | 621 (60.5%) | 0.665 | 0.908 | 0.588 | 1.403 | |
Over weight | 312 (16.2%) | 127 (40.7%) | 185 (59.3%) |  – | 1 |  – |  – | |
Opportunistic infection | No | 1668 (86.9%) | 693 (41.5%) | 975 (58.5%) | 0.964 | 1.011 | 0.638 | 1.602 |
Yes | 252 (13.1%) | 105 (41.7%) | 147 (58.3%) |  – | 1 |  – |  – | |
ART regimen type | AZT + 3TC + NVP | 1272 (66.2%) | 533 (41.9%) | 739 (58.1%) | 0.046 | 5.873 | 1.028 | 33.550 |
AZT + 3TC + EFV | 570 (29.7%) | 234 (41.1%) | 336 (58.9%) | 0.055 | 5.566 | 0.962 | 32.198 | |
AZT + 3TC + ATV/r | 66 (3.4%) | 29 (43.9%) | 37 (56.1%) | 0.062 | 6.273 | 0.911 | 43.181 | |
AZT + 3TC + NVP/r | 12 (0.6%) | 2 (16.7%) | 10 (83.3%) |  – | 1 |  – |  – | |
Time of visit (Month) | Base line visit | 320 (16.7%) | 160 (50.0%) | 160 (50.0%) | 0.001 | 1.569 | 1.196 | 2.058 |
6Â month | 320 (16.7%) | 141 (44.1%) | 179 (55.9%) | 0.132 | 1.228 | 0.940 | 1.603 | |
12Â month | 320 (16.7%) | 114 (35.6%) | 206 (64.4%) | 0.289 | 0.856 | 0.642 | 1.141 | |
18Â month | 320 (16.7%) | 128 (40.0%) | 192 (60.0%) | 0.789 | 1.037 | 0.794 | 1.354 | |
24Â month | 320 (16.7%) | 130 (40.6%) | 190 (59.4%) | 0.618 | 1.067 | 0.827 | 1.376 | |
30 month | 320 (16.7%) | 125 (39.1%) | 195 (60.9%) |  – | 1 |  – |  – |